NCT06006741Not yet recruitingPhase 1
Universal CAR-T Cells Targeting Multiple Myeloma
Universal CAR-T Cells for the Treatment of Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 8 Aug 2023
- Start date
- 30 Jun 2027
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT06006741
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- From 30 Jun 2027 to the primary completion date, 1 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Previous related CAR-T cell therapy
Other illness
- Uncontrolled active infection
- Active hepatitis B or hepatitis C infection
- Any uncontrolled active medical disorder that would preclude participation
- HIV infection
Other
- Pregnant or lactating women
Who the study is looking for
- Patients with confirmed multiple myeloma failed curative treatment options (including autologous or allogeneic SCT).
- Complete remission (CR) cannot be achieved after at least 2 prior therapy regimens.
- High risk MM in CR1 or CR2 and not eligible for SCT because of age or comorbid diseases.
- Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year).
- Relapsed after prior autologous or allogenic SCT with residual disease after at least 1 prior therapy and not eligible for allogeneic SCT.
- Residual disease after primary therapy and not eligible for ASCT
- Expected survival \> 12 weeks• Creatinine \< 2.5 mg/dl• ALT (alanine aminotransferase)/AST (aspartate aminotransferase) \< 3x normal
- Bilirubin \< 2.0 mg/dl
- Any relapse after prior SCT is eligible regardless of other prior therapy
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
- Voluntary informed consent is signed
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.